Irish biotech firm Elan rejects new Royalty bid

June 10, 2013

Irish biotechnology company Elan rejected on Monday the latest takeover bid from US group Royalty Pharma worth about $7.9 billion (6.0 billion euros).

"Elan Corporation plc today announced that its board of directors ... has rejected the revised bid from privately held investment firm Royalty Pharma," it said in a statement.

"The value gap between the underlying value of Elan plc and the totality of its business platform and the Royalty Pharma/Echo bid remains significant," it added.

On Friday, Royalty Pharma had tabled an offer worth up to $15.50 per Elan share, made up of $13.00 in cash and up to $2.50 depending on the performance of its blockbuster multiple-sclerosis drug .

Elan had sold its half of Tysabri in February to US development partner Biogen Idec Inc. for $3.25 billion. The Dublin-based company has retained a royalty stream from sales of the drug.

Royalty's third takeover offer compared with the previous bid of $12.50 per share in cash, worth $6.4 billion. Elan has repeatedly rejected Royalty's approaches.

- Newswires contributed ti this report -

Explore further: Royalty Pharma offers to buy Elan for about $6.5B (Update)

Related Stories

Elan moves to deter takeover bid

March 4, 2013

(AP)—Irish drug maker Elan Corp. announced Monday it will pay shareholders a recurring special dividend linked to the sales of the multiple sclerosis treatment Tysabri.

US approves new multiple sclerosis capsules

March 27, 2013

The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

Elan enters $1B royalty deal with Theravance

May 13, 2013

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Judge halts Royalty Pharma's bid for Elan stock

June 4, 2013

Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the ...

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.